Clinical Trial: A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)

U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07006025) titled 'A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)' on May 20.

Brief Summary: The goal of this clinical trial is to learn about the safety and effectiveness of the combination drug Tetrahydrouridine (THU) and decitabine (DEC) to treat patients with relapsed or refractory myelodysplastic syndrome. The main questions it aims to answer are:

* Does the combination drug exhibit hematological and nonhematological toxicity?

* Does the combination drug improve health status and reduce the number of days of hospitalization?

Participants will:

* Take tetrahydrouridine and decitabine once ...